ATCC

🌍ATCC Steps Up in the Fight Against Mpox Outbreak 🌍 In light of the recent declaration by the WHO of mpox as a public health emergency due to a new strain spreading in Africa, ATCC is committed to supporting global health initiatives. Our team is working tirelessly to provide high-quality biological materials and research support to scientists and healthcare professionals battling this outbreak. 🔬 What We’re Doing: - Supplying Critical Research Materials: ATCC is providing essential mpox virus strains and related biological materials to researchers worldwide. - Enhancing Diagnostic Capabilities: We’re aiding in the development and distribution of accurate diagnostic tools to detect and monitor the spread of mpox. - Supporting Vaccine Development: Our resources are used in the development of vaccines to combat the new mpox strain. 💪 Together, we can make a difference. Stay informed, stay safe, and support the fight against mpox. Visit our mpox research page to learn more --> https://lnkd.in/eXihSv5V #ATCC #PublicHealth #Mpox #GlobalHealth #Research #Vaccines

Essential culture reagents such as media, #sera, and supplements support cell survival, proliferation, and biological function. We provide scientists with these reagents to aid with consistent, reliable, and #reproducible results. https://ow.ly/v3Ni50SeBu2

🎙️ In this episode of the Behind the Biology podcast, we dive into the fascinating world of microbial forensics with Professor James Crill. Tune in to hear him unravel the mysteries behind the origins of bacteria and yeast --> https://lnkd.in/eNwHEYa6

ATCC is committed to providing researchers with the credible, cutting-edge models they need to make breakthroughs in diagnostics development, #drugdiscovery, and translational #research. Check out our latest new products: https://ow.ly/lUA050Sc01x

ATCC Hot Job Alert! Check out these new career opportunities and apply today! --> https://lnkd.in/eaFMJBfR

Have you heard about our work with the Eumycetozoa Project? The unique, robust life cycle of #eumycetozoa (a type of slime mold) shows promise in the development of novel therapies for diseases such as #cancer and dementia. https://ow.ly/zP4s50ScGf6

It is estimated that 50% of biological research data is irreproducible, and a significant portion of this irreproducibility is associated with research methodology, data analysis, gaps in data provenance, and poor biological materials. To address this need, ATCC has worked with our collaborators to create the #ATCCGenomePortal and ATCC Cell Line Land to better establish a standard for reproducible results. https://ow.ly/RY9Z50SaOhM

Antimicrobial resistance is spreading quickly—we need new treatments and we need them fast. Discover how you can elevate your #drugdiscovery research with credible antimicrobial-resistant strains from ATCC. https://ow.ly/wLQO50Schbn

The Biomedical Advanced Research and Development Authority (BARDA) is supporting the development of next-generation COVID-19 vaccines, which have the potential to expand the breadth of coverage against existing and future variants, extend the duration of protection, and offer better protection in the prevention of illness and transmission over current vaccine technologies. The vaccines developed under Project NextGen include an oral mucosal vaccine, a live attenuated virus vaccine, an intranasal vaccine, and an mRNA vaccine. While existing vaccines against COVID-19 are still effective, they are less capable of reducing infection and transmission over time. Similarly, previously authorized monoclonal antibody therapeutics are not effective against current circulating strains. In support of these Project NextGen efforts, ATCC was awarded $87 million from BARDA through the Administration for Strategic Preparedness and Response (ASPR) to coordinate all tasks for a cradle-to-grave chain of custody, storage, monitoring, and distribution for up to 4.3 million NextGen COVID-19 biological specimens. ATCC will provide a long-term storage facility for COVID-19 biological specimens and distribute them to BARDA-approved facilities in support of the development of vaccines, therapeutics, and potential assays for current and future COVID-19 variants. This work with BARDA underlines ATCC’s commitment to global health and pandemic preparedness.  

The #Adenovirus Type 5 Reference Material (ATCC® VR-1516™) is available! Because of the necessary differences in manufacturing between new lots and the original 2001 production, there are a few changes to the reference material as compared to previous stocks. We have provided a comparison below for reference. Check out the comparison: https://ow.ly/7sRu50SbehK